Earnings calls

Entero Healthcar concall ledger

Every earnings call for ENTERO — management tone, guidance, KPIs and promise tracking, quarter by quarter.

ENTERO · 6 transcripts · Consumer Services · latest Q3 FY26

Q3 FY26Published 13 Feb 2026Call held 13 Feb 2026

ENTERO Q3 FY26 Earnings Call Transcript & Analysis

Revenue₹1,707 cr+26% YoYEBITDA₹68 cr+36% YoYEBITDA Margin4%PAT₹34 cr+15% YoYGross Margin10.1%

Revenue ₹1,707 cr (+26% YoY); EBITDA ₹68 cr (+36% YoY); EBITDA Margin 4% (+0% YoY). Revenue grew 26% YoY to INR1,707 crores, with organic growth at 17.1%.

Read full transcript & analysis

Q2 FY26Published 13 Nov 2025Call held 13 Nov 2025

ENTERO Q2 FY26 Earnings Call Transcript & Analysis

Revenue₹1,571 cr+21% YoYEBITDA₹62 cr+46% YoYEBITDA Margin4%+1% YoYPAT₹37 cr+41% YoYPAT Margin2.3%

Revenue ₹1,571 cr (+21% YoY); EBITDA ₹62 cr (+46% YoY); EBITDA Margin 4.0% (+1% YoY). Revenue grew by 20.8% YoY to INR1,571 crores in Q2 FY26.

Read full transcript & analysis

Q1 FY26Published 11 Aug 2025Call held 11 Aug 2025

ENTERO Q1 FY26 Earnings Call Transcript & Analysis

Revenue₹1,404 cr+28% YoYEBITDA₹50 cr+66% YoYEBITDA Margin3.6%PAT₹30 cr+47% YoYGross Margin9.9%

Revenue ₹1,404 cr (+28% YoY); EBITDA ₹50 cr (+66% YoY); EBITDA Margin 3.6%. Revenue grew 28% year-on-year to ₹1,404 crores, with like-to-like growth at 31%.

Read full transcript & analysis

Q4 FY25Published 28 May 2025Call held 28 May 2025

ENTERO Q4 FY25 Earnings Call Transcript & Analysis

FY25 Revenue₹5,096 cr+30% YoYFY25 EBITDA₹172 cr+53% YoYFY25 EBITDA Margin3.4%FY25 PAT₹107 cr+170% YoY

FY25 Revenue ₹5,096 cr (+30% YoY); FY25 EBITDA ₹172 cr (+53% YoY); FY25 EBITDA Margin 3.4%. FY25 Revenue crossed ₹5,000 crores, reaching ₹5,096 crores, a 30% YoY growth.

Read full transcript & analysis

Q3 FY25Published 30 May 2024Call held 30 May 2024

ENTERO Q3 FY25 Earnings Call Transcript & Analysis

Revenue₹3,922 cr+19% YoYEBITDA₹112 cr+75% YoYEBITDA Margin2.9%PAT₹40 crNormalized ROCE10.2%

Revenue ₹3,922 cr (+19% YoY); EBITDA ₹112 cr (+75% YoY); EBITDA Margin 2.9%. FY24 Total Operating Revenue reached INR 3,922 crores, marking a 19% YoY increase, significantly outpacing the pharmaceutical industry growth rate of 7.6%.

Read full transcript & analysis

Q2 FY25Published 13 Nov 2024Call held 13 Nov 2024

ENTERO Q2 FY25 Earnings Call Transcript & Analysis

Revenue₹1,301 cr+31% YoYEBITDA₹42 cr+49% YoYEBITDA Margin3.3%PAT₹26 cr+290% YoY

Revenue (Q2 FY25) ₹1,301 cr (+31% YoY); EBITDA (Q2 FY25) ₹42 cr (+49% YoY); EBITDA Margin (Q2 FY25) 3.3%. Consolidated revenue for Q2 FY25 stood at ₹1,301 crores, marking a robust 31% year-on-year increase.

Read full transcript & analysis